Open access
2026
LINC00460 drives clear cell renal cell carcinoma progression via complement/coagulation and p53 pathways: a potential therapeutic target.
Findings establish LINC00460 as an oncogenic driver in ccRCC and a promising target for both diagnosis and precision therapy and identifies cinchonine and iproniazid as candidate therapeutic agents.
Bo Dong, Songtao Liu, Wenyu Wang et al.
· American journal of translat... · 0 citations